Pharmsynthez plans to raise 500 million rubles ($16.3 million) in a stock market float this November, delivering a rare boost to the country’s flagging IPO market, the pharmaceutical company said Monday.
The funds will be used to build a new production plant in St. Petersburg and make strategic acquisitions overseas, the company said in a statement.
“There is enormous potential for growth in innovative medicine production in Russia, and Pharmsynthez is extremely well placed to capitalize on that growth,” chief executive Dmitry Genkin, who owns 25 percent, said in a statement.
A source familiar with the deal said about a 30 percent stake in the group could be floated.
(Reuters)
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.
